These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16911688)

  • 1. Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.
    Ariizumi K; Ohara S; Koike T; Inomata Y; Iijima K; Sekine H; Noguchi M; Sugiyama K; Eda Y; Kayaba S; Kawamura M; Shimosegawa T
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1428-34. PubMed ID: 16911688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis.
    Kawamura M; Ohara S; Koike T; Iijima K; Suzuki H; Kayaba S; Noguchi K; Abe S; Noguchi M; Shimosegawa T
    J Gastroenterol Hepatol; 2007 Feb; 22(2):222-6. PubMed ID: 17295875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
    He XX; Zhao YH; Hao YT
    Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
    Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
    Ando T; Kato H; Sugimoto N; Nagao Y; Seto N; Hongo H; Kajikawa H; Isozaki Y; Shimozawa M; Naito Y; Yoshida N; Ishizaki T; Yoshikawa T
    Dig Dis Sci; 2005 Sep; 50(9):1625-31. PubMed ID: 16133961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.
    Ji S; Kim HS; Kim JW; Jee MK; Park KW; Uh Y; Lee DK; Song JS; Baik SK; Kwon SO
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1381-7. PubMed ID: 16911680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
    Kawai T; Kawakami K; Mikinori K; Takei K; Itoi T; Moriyasu F; Takagi Y; Aoki T; Watanebe K; Matsumoto Y; Rimbara E; Noguchi N; Sasatsu M
    Hepatogastroenterology; 2007 Mar; 54(74):649-54. PubMed ID: 17523342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
    Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
    Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
    Zendehdel N; Biramijamal F; Hossein-Nezhad A; Zendehdel N; Sarie H; Doughaiemoghaddam M; Pourshams A
    Arch Iran Med; 2010 Sep; 13(5):406-12. PubMed ID: 20804307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
    Furuta T; Sugimoto M; Shirai N; Ishizaki T
    Pharmacogenomics; 2007 Sep; 8(9):1199-210. PubMed ID: 17924835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis.
    Ohkusa T; Maekawa T; Arakawa T; Nakajima M; Fujimoto K; Hoshino E; Mitachi Y; Hamada S; Mine T; Kawahara Y; Nagai T; Aoyama N; Yoshida N; Tadokoro K; Chida N; Konda Y; Seno H; Shimatani T; Inoue M; Sato N
    Aliment Pharmacol Ther; 2005 Jun; 21(11):1331-9. PubMed ID: 15932363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.
    Kawamura M; Ohara S; Koike T; Iijima K; Suzuki J; Kayaba S; Noguchi K; Hamada S; Noguchi M; Shimosegawa T;
    Aliment Pharmacol Ther; 2003 Apr; 17(7):965-73. PubMed ID: 12656699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C19 genotype and the PPIs--focus on rabeprazole.
    Lim PW; Goh KL; Wong BC
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
    Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
    J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
    Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
    Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
    Furuta T; Shirai N; Watanabe F; Honda S; Takeuchi K; Iida T; Sato Y; Kajimura M; Futami H; Takayanagi S; Yamada M; Ohashi K; Ishizaki T; Hanai H
    Clin Pharmacol Ther; 2002 Oct; 72(4):453-60. PubMed ID: 12386647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype.
    Ando T; Ishikawa T; Kokura S; Naito Y; Yoshida N; Yoshikawa T
    Dig Dis Sci; 2008 Apr; 53(4):933-7. PubMed ID: 17934830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.